LncRNA HCG18 Promotes Clear Cell Renal Cell Carcinoma Progression by Targeting miR-152-3p to Upregulate RAB14

Abstract

Background Long noncoding RNAs (lncRNAs) have been regarded as crucial regulators in many cancers, including clear cell renal cell carcinoma (ccRCC). This research aimed to explore the biological role and molecular mechanism of lncRNA HCG18 in ccRCC. Materials and Methods The expression levels of HCG18, miR-152-3p and RAB14 were examined by RT-qPCR. Cell viability, migration and invasion were examined by CCK-8 and transwell assays. Luciferase reporter and RIP assays were adopted to verify the interaction between miR-152-3p and HCG18 or RAB14 . Results It was found that HCG18 expression was highly expressed in ccRCC tissues and cells, and patients with high expression of HCG18 had a short overall survival time. Moreover, HCG18 depletion attenuated ccRCC cell viability, migration and invasion. In addition, miR-152-3p was confirmed as a downstream target of HCG18 and was inversely regulated by HCG18 , and RAB14 was a target of miR-152-3p . Functional assays demonstrated that miR-152-3p silencing or RAB14 addition abolished the inhibitory effects of HCG18 knockdown on ccRCC progression. Conclusion The results of the present study indicated that HCG18 accelerated the development and progression of ccRCC by upregulating RAB14 via sponging miR-152-3p , suggesting a potential therapeutic target for patients with ccRCC.

Identification and Validation of a Ferroptosis-Related Long Non-Coding RNA (FRlncRNA) Signature to Predict Survival Outcomes and the Immune Microenvironment in Patients With Clear Cell Renal Cell Carcinoma

“…Ferroptosis regulated by lncRNAs was known to participate in the various progression stages of ccRCC, such as invasion, metastasis, prognosis, and chemoresistance. The limitation of multiple studies is that they only target the single or a few lncRNAs investigated for ccRCC ( Ju et al, 2020 ; Zhu et al, 2020 ; Yang et al, 2021 ). To date, novel biomarkers have not been reported to be explored via the lncRNAs’ expression profiles of The Cancer Genome Atlas (TCGA) database to predict the prognosis of ccRCC.…”

Identification of an autophagy-related 12-lncRNA signature and evaluation of NFYC-AS1 as a pro-cancer factor in lung adenocarcinoma

“…SNHG10 has been identified as oncogenic in bladder cancer (Jiang et al, 2018), hepatocellular carcinoma (Lan et al, 2019), osteosarcoma (He et al, 2020), glioma (Jin et al, 2020), non-small cell lung cancer (Zhang et al, 2020b;Liang et al, 2020), acute myeloid leukemia (Xiao et al, 2021), and gastric cancer (Yuan et al, 2021;Zhang et al, 2021). HCG18 was found to be involved in several tumors (Xi et al, 2017;Li et al, 2018b;Wang et al, 2018;Li et al, 2019b;Li et al, 2020a;Liu et al, 2020;Ma et al, 2020;Zhang and Lou, 2020;Zou et al, 2020;Yang et al, 2021;Zhu et al, 2021) and recognized as the driver of LUAD (Li et al, 2020b). It is worth mentioning that although HCG18 is linked to a better prognosis in our risk signature, its expression is higher in tumors compared to adjacent normal tissues, which may be due to the compensatory effect of this lncRNA as a potential tumor suppressor.…”

LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b

“…HCG18 has been identified as a carcinogenic gene in several cancer types (Li et al 2020a ; Yang et al 2021 ). For example, Li et al demonstrated that knockdown of HCG18 repressed cell proliferation and metastasis in nasopharyngeal carcinoma progression (Li et al 2019 ).…”

“…For example, Li et al demonstrated that knockdown of HCG18 repressed cell proliferation and metastasis in nasopharyngeal carcinoma progression (Li et al 2019 ). Furthermore, a recent study demonstrated that HCG18 acts as a ceRNA for miR-152–3p, thereby derepressing its target gene DNAJB12 to promote the development of gastric cancer (Yang et al 2021 ; Ma et al 2020 ). Using starBase, we also identified a binding relationship between HCG18 and miR-152–3p.…”